-
- Abdul Rahman Jazieh
- Department of Oncology, King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia
-
- Hakan Akbulut
- Ankara University School of Medicine, Department of Medical Oncology, Ankara, Turkey
-
- Giuseppe Curigliano
- European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, and University of Milan, Milan, Italy
-
- Alvaro Rogado
- Fundación ECO, Madrid, Spain
-
- Abdullah Ali Alsharm
- King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia
-
- Evangelia D. Razis
- Hygeia Hospital, Athens, Greece
-
- Layth Mula-Hussain
- Radiation Oncology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
-
- Hassan Errihani
- National Institute of Oncology, Mohammed V University, Rabat, Morocco
-
- Adnan Khattak
- Fiona Stanley Hospital, Perth, Western Australia, Australia
-
- Roselle B. De Guzman
- Manila Central University-Filemon D. Tanchoco Medical Foundation Hospital, Caloocan City, Philippines
-
- Clarissa Mathias
- Núcleo de Oncologia da Bahia, Grupo Oncoclínicas, Salvador, Bahia, Brazil
-
- Mohammad Omar Farouq Alkaiyat
- Department of Oncology, King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia
-
- Hoda Jradi
- King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia
-
- Christian Rolfo
- University of Maryland School of Medicine, Baltimore, MD
説明
<jats:sec><jats:title>PURPOSE</jats:title><jats:p> The COVID-19 pandemic affected health care systems globally and resulted in the interruption of usual care in many health care facilities, exposing vulnerable patients with cancer to significant risks. Our study aimed to evaluate the impact of this pandemic on cancer care worldwide. </jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p> We conducted a cross-sectional study using a validated web-based questionnaire of 51 items. The questionnaire obtained information on the capacity and services offered at these centers, magnitude of disruption of care, reasons for disruption, challenges faced, interventions implemented, and the estimation of patient harm during the pandemic. </jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p> A total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), staff shortage (17.98%), and restricted access to medications (9.83%). Missing at least one cycle of therapy by > 10% of patients was reported in 46.31% of the centers. Participants reported patient exposure to harm from interruption of cancer-specific care (36.52%) and noncancer-related care (39.04%), with some centers estimating that up to 80% of their patients were exposed to harm. </jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p> The detrimental impact of the COVID-19 pandemic on cancer care is widespread, with varying magnitude among centers worldwide. Additional research to assess this impact at the patient level is required. </jats:p></jats:sec>
収録刊行物
-
- JCO Global Oncology
-
JCO Global Oncology (6), 1428-1438, 2020-11
American Society of Clinical Oncology (ASCO)